熱門資訊> 正文
Guardant已批准适用于Braftovi的Guardant 360配套诊断
2026-01-22 22:19
- The US FDA approved Guardant Health's (GH) Guardant360 CDx companion diagnostic for use in determining which patients could benefit from Pfizer's (PFE) Braftovi (encorafenib) as a colorectal cancer treatment.
- The test is used with patients with BRAF V600E-mutant metastatic colorectal cancer.
- Guardant360 CDx uses a small amount of blood to find genetic mutations.
More on Guardant Health
- Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth
- 44th Annual J.P. Morgan Healthcare Conference
- Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Guardant Health guides Q4 and FY25 revenue above consensus
- Guardant Health is the top performing healthcare services stock YTD
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
